WARREN, N.J., Jan. 19 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG) today announced the filing of a registration statement with the Securities and Exchange Commission for an offering of 2,416,000 shares of its common stock. Of the shares offered, 2,000,000 shares are being offered by Celgene for its own account. The remaining 416,000 shares are being sold on behalf of John Hancock Mutual Life Insurance Company and its affiliates. Celgene will also grant to the underwriters an option to purchase an additional 362,400 shares of common stock to cover over-allotments.
Celgene intends to use its net proceeds from this offering to further the commercialization and clinical development of Thalomid(R), to accelerate the advancement of its IMiD(TM) and SelCID(TM) product development programs, to further develop its chiral chemistry program, including ATTENADE(TM), and for general corporate purposes. Celgene will not receive any proceeds from the sale of shares by John Hancock Mutual Life Insurance Company and its affiliates.
J. P. Morgan & Co. and Prudential Vector Healthcare Group, a unit of Prudential Securities Incorporated are the joint lead managers of the offering. U.S. Bancorp Piper Jaffray is acting as co-manager.
Celgene Corporation is an independent biopharmaceutical company engaged in the discovery, development and commercialization of small molecule pharmaceuticals. Celgene is headquartered in Warren, New Jersey.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. A written prospectus for this offering is not yet available. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include actions by the FDA and other regulatory authorities, and those factors detailed in the Company's filings with the Securities and Exchange Commission such as 10K, 10Q, and 8K reports.
SOURCE Celgene Corporation
CONTACT: Robert J. Hugin, SVP and CFO of Celgene Corporation, 732-271-4102